Mounjaro KwikPen 15 mg is the highest strength, offering maximum therapeutic effect for adults with type 2 diabetes who require stronger metabolic support.
| Composition | Tirzepatide |
| Manufacturer | Eli Lilly and Company |
| Packing | 1 Prefilled Pen of 2.4ml |
| Prescribed For | Type 2 Diabetes and Weight management |
| Expiry | December 2027 |
Mounjaro KwikPen 10 mg/0.6 ml is a once-weekly injectable medicine used to improve blood sugar control in adults with type 2 diabetes. It works by increasing insulin release, reducing appetite, and slowing digestion to help maintain healthy glucose levels.
| Composition | Tirzepatide |
| Manufacturer | Eli Lilly and Company |
| Packing | 1 Prefilled Pen of 2.4ml |
| Prescribed For | Type 2 Diabetes and Weight management |
| Expiry | December 2027 |
Mounjaro KwikPen 7.5 mg is an injectable prescription medicine used once weekly to help control blood sugar in adults with type 2 diabetes. It works by improving insulin release, reducing appetite, and slowing digestion.
| Composition | Tirzepatide |
| Manufacturer | Eli Lilly and Company |
| Packing | 1 Prefilled Pen of 2.4ml |
| Prescribed For | Type 2 Diabetes and Weight management |
| Expiry | December 2027 |
Mounjaro KwikPen 5 mg is a maintenance dose that enhances blood sugar regulation and aids weight control in adults with type 2 diabetes.
| Composition | Tirzepatide |
| Manufacturer | Eli Lilly and Company |
| Packing | 1 Prefilled Pen(s) Of 2.4ml |
| Prescribed For | Type 2 Diabetes and Weight management |
| Expiry | December 2027 |
Mounjaro KwikPen 2.5 mg is the starting dose used to help the body adjust to Tirzepatide. It supports type 2 diabetes management by improving insulin release and controlling appetite.
| Composition | Tirzepatide |
| Manufacturer | Eli Lilly and Company |
| Packing | 0.6 ml |
| Prescribed For | Type 2 Diabetes and Weight management |
| Expiry | December 2027 |
